Description
What Is Super Tadalis SX?
Super Tadalis SX is a fixed-dose combination tablet containing tadalafil 20 mg and dapoxetine 60 mg for the concurrent treatment of erectile dysfunction (ED) and premature ejaculation (PE) in adult men. It combines two distinct classes of agent: tadalafil, a long-acting phosphodiesterase type 5 (PDE5) inhibitor that provides erection support for up to 36 hours, and dapoxetine, the only short-acting selective serotonin reuptake inhibitor (SSRI) specifically developed and licensed for on-demand use in premature ejaculation. The combination targets both male sexual disorders simultaneously in a single tablet, reducing the need for separate prescriptions and simplifying dosing for men who have both conditions.
The pairing of tadalafil with dapoxetine is clinically complementary. Tadalafil’s long duration of action (up to 36 hours, earned it the description “the weekend pill”) removes performance-related timing pressure and can itself reduce anxiety-related PE triggers. Dapoxetine’s rapid onset (~1 hour) and short elimination half-life (~1.5 hours) make it suitable for on-demand dosing without the continuous SSRI burden of daily dosing. Together they address the two most common male sexual complaints — erectile difficulty and rapid ejaculation — with a pharmacological profile optimised for spontaneous, unplanned sexual activity.
Mechanism of Action
Tadalafil 20 mg — Long-Acting PDE5 Inhibition
Tadalafil selectively inhibits PDE5, the cyclic guanosine monophosphate (cGMP)-degrading phosphodiesterase expressed in corpus cavernosum smooth muscle. Sexual stimulation triggers nitric oxide (NO) release from penile nerve endings and endothelium, activating guanylyl cyclase and generating cGMP. cGMP causes smooth muscle relaxation, arterial dilation, and venous occlusion — the vascular events that constitute penile erection. Tadalafil prolongs cGMP accumulation by preventing its breakdown, amplifying the erectile response to sexual stimulation. Tadalafil’s selectivity for PDE5 over PDE6 (retinal) is higher than sildenafil’s, explaining its lower incidence of visual disturbances. Its plasma half-life of approximately 17.5 hours explains the extended 36-hour window of efficacy, distinctly longer than sildenafil (4–5 hours) or vardenafil (4–5 hours).
Dapoxetine 60 mg — Short-Acting SSRI for Ejaculatory Delay
Dapoxetine is a short-acting SSRI with a pharmacokinetic profile unique among SSRIs: it has a rapid Tmax of approximately 1–2 hours and a short initial half-life (~1.5 hours), falling to negligible plasma levels within 24 hours. This distinguishes it from antidepressant SSRIs (fluoxetine, paroxetine, sertraline) that accumulate over weeks and require daily dosing. Dapoxetine’s on-demand profile was specifically engineered for PE: it provides sufficient SSRI action at peak plasma concentration to significantly delay ejaculation through inhibition of the presynaptic serotonin transporter (SERT), raising synaptic 5-HT at spinal serotonergic synapses in the ejaculatory control pathway. Elevated 5-HT increases descending inhibitory tone on the spinal ejaculatory generator via 5-HT₁B and 5-HT₂C receptors, raising the ejaculatory threshold and prolonging intravaginal ejaculatory latency time (IELT). Clinical trials demonstrated dapoxetine 60 mg approximately doubles or triples IELT compared with placebo in men with lifelong and acquired PE.
Indications
Concurrent Erectile Dysfunction and Premature Ejaculation
Super Tadalis SX is indicated for adult men with both erectile dysfunction and premature ejaculation where management of both conditions simultaneously is required. It is appropriate for men in whom separate PDE5 inhibitor and PE therapy is desired in a single dosage form, men who prefer tadalafil’s extended duration of action over shorter-acting sildenafil or vardenafil, and men who want an on-demand PE treatment without the need for a continuous daily SSRI.
Clinical Preference for Tadalafil Over Sildenafil
Some men prefer tadalafil to sildenafil or vardenafil for ED management on the basis of its longer duration, its lower likelihood of visual side effects (tadalafil has greater PDE5/PDE6 selectivity), or its documented efficacy in men with more severe ED, diabetes-related ED, or post-radical prostatectomy ED. For these men, Super Tadalis SX provides the same dapoxetine-based PE management within a tadalafil-based framework rather than a sildenafil-based one.
Dosage and Administration
Standard dose: One tablet (tadalafil 20 mg + dapoxetine 60 mg) taken 1–3 hours before anticipated sexual activity.
Timing window: 1–3 hours before activity. Tadalafil onset is typically 30–60 minutes; its 36-hour duration means timing is flexible. Dapoxetine Tmax is 1–2 hours, defining the minimum lead time. The combined recommendation of 1–3 hours reflects dapoxetine’s onset requirement within tadalafil’s broad activity window.
Frequency: On-demand; maximum one tablet per 24-hour period. Dapoxetine’s short half-life means its PE effect does not substantially accumulate with repeated doses; tadalafil does accumulate slightly with frequent dosing but remains within the approved dose range.
Food effect: Tadalafil is minimally affected by food, and dapoxetine’s absorption is also not significantly altered by food — Super Tadalis SX may be taken with or without food, which is a clinical advantage over sildenafil-based combinations.
Renal impairment: Use with caution in moderate impairment; avoid in severe renal impairment (both components).
Hepatic impairment: Avoid in moderate to severe hepatic impairment.
Contraindications
- Organic nitrates (absolute): GTN, isosorbide mononitrate, isosorbide dinitrate, amyl nitrite — combined severe hypotension with tadalafil. The 36-hour half-life of tadalafil means nitrate administration must be separated by at least 48 hours.
- MAO inhibitors (absolute): Dapoxetine — serotonin syndrome risk. Do not use within 14 days of stopping a MAOI.
- Thioridazine: Contraindicated with dapoxetine — QTc prolongation risk.
- Riociguat: Contraindicated with tadalafil — severe hypotension.
- Hypersensitivity to tadalafil, dapoxetine, or excipients.
- Severe cardiovascular disease where sexual activity is contraindicated.
- Severe hepatic or severe renal impairment.
- Uncontrolled hypotension or hypertension.
- Hereditary galactose intolerance (lactose in some dapoxetine formulations).
Warnings and Precautions
Vasovagal syncope with dapoxetine: Dapoxetine carries a clinically significant and unique warning not shared by other SSRIs: vasovagal (neurocardiogenic) syncope. Dapoxetine can trigger parasympathetically mediated syncope — sudden loss of consciousness from blood pressure and heart rate drop — in susceptible individuals, most commonly on first dose. Men should take their first dose sitting or lying down and remain so for the first 3 hours. They should not drive, operate heavy machinery, or engage in activities requiring full alertness for at least 3 hours after the first dose and any dose change.
Orthostatic hypotension: Dapoxetine increases the risk of orthostatic hypotension, particularly when combined with the vasodilatory effect of tadalafil and concurrent antihypertensive agents. Patients should rise slowly from sitting or lying positions. Alcohol significantly amplifies this risk.
Nitrate interaction and 48-hour window: Because tadalafil has a half-life of ~17.5 hours, its vasodilatory effects extend much longer than sildenafil’s. Any nitrate requirement (including during cardiac emergencies) must be communicated to emergency clinicians — nitrates are contraindicated for at least 48 hours after tadalafil use, not 24 hours as with sildenafil.
Serotonin syndrome: Dapoxetine carries serotonin syndrome risk with concurrent serotonergic medications.
Priapism: As with all PDE5 inhibitors, prolonged erection (>4 hours) requires immediate medical attention.
Adverse Effects
- Tadalafil-related: Headache, back pain and myalgia (tadalafil-specific, related to PDE11 inhibition in skeletal muscle), flushing, nasal congestion, dyspepsia. Visual effects are less common than with sildenafil.
- Dapoxetine-related: Nausea (most common), dizziness, headache, diarrhoea, dry mouth, insomnia. Vasovagal syncope (see Warnings). Decreased libido uncommonly.
- Additive: Hypotension and dizziness (combined vasodilatory effects of tadalafil + dapoxetine’s orthostatic effects).
Drug Interactions
- Nitrates: Absolute contraindication — 48-hour window required after tadalafil use.
- MAOIs and thioridazine: Absolute contraindication (dapoxetine).
- CYP3A4 inhibitors (ritonavir, ketoconazole, itraconazole): Significantly increase tadalafil and dapoxetine exposure — dose reduction or avoidance required.
- Alpha-blockers: Additive hypotension with tadalafil. The combination can cause symptomatic hypotension, particularly at peak plasma concentrations. Use lowest doses of both agents.
- Alcohol: Significantly potentiates dapoxetine-associated orthostatic hypotension and syncope risk — advise patients to minimise alcohol consumption when taking Super Tadalis SX.
- Other serotonergic agents: Increased serotonin syndrome risk with concurrent SSRIs, SNRIs, triptans, tramadol, lithium, St John’s Wort.
- Antihypertensives: Additive blood pressure reduction with tadalafil.
Storage
Store below 30°C in a cool, dry place away from direct sunlight and moisture. Keep in original blister packaging until use. Keep out of reach of children. Do not use after the expiry date.
Related Products
For sildenafil-based ED + PE combinations, see Filagra DXT 100+30 mg and Filagra DXT Plus 100+60 mg. For dapoxetine 60 mg as a standalone PE treatment without ED management, see Vriligy 60 mg Tablets.
References
- National Library of Medicine MedlinePlus. Tadalafil. Available at: https://medlineplus.gov/druginfo/meds/a604008.html
- National Library of Medicine DailyMed. Dapoxetine hydrochloride. Available at: https://dailymed.nlm.nih.gov
- Mayo Clinic. Tadalafil (Oral Route). Available at: https://www.mayoclinic.org
- Burnett AL, Nehra A, Breau RH, et al. Erectile dysfunction: AUA guideline. J Urol. 2018;200(3):633–641. PubMed PMID: 29746562
- Althof SE, McMahon CG, Waldinger MD, et al. An Update of the International Society of Sexual Medicine’s guidelines for the diagnosis and treatment of premature ejaculation (PE). Sex Med. 2014;2(2):60–90. PubMed PMID: 25356297
- McMahon CG, et al. Dapoxetine for the treatment of premature ejaculation: summary of two phase III trials. J Sex Med. 2010;7(1 Pt 1):256–268. PubMed PMID: 19694928


Reviews
There are no reviews yet.